News Hub | News Direct

Stem Cell Innovators: 4 Companies Advancing Regenerative Medicine

ADIA FATE MESO CRSP

Stem cells have a unique ability—they can transform into different types of cells, making them a game-changer in regenerative medicine. From repairing heart tissue after a heart attack to potentially reversing neurodegenerative diseases like Alzheimer's, the possibilities are vast. While their potential has been known for years, challenges such as immune rejection and difficulty in controlling cell differentiation have slowed progress. However, advances in DNA and RNA research have given scientists better control over the process, opening the door to real-world treatments. The stem cell industry is now shifting from theoretical breakthroughs to tangible medical applications. In 2024, the global stem cell market was valued at $15.1 billion and is projected to grow at an annual rate of 11.41% through 2030. This surge is driven by increased research, growing demand for stem cell banking, and major strides in precision medicine. Now, let's take a closer look at a few stocks making waves in this sector. ADIA Nutrition Inc. (OTC Pink: ADIA) is quickly becoming a company to watch in the stem cell and regenerative medicine space. The company operates through two main divisions: a nutritional supplement business and its medical division, Adia Med, which is focused on advanced stem cell therapies. ADIA’s recent announcements and strong growth trajectory suggest the company is positioning itself as a leader in this high-potential sector. One of the company's standout moves is its commitment to expanding stem cell treatments across the United States. In January 2025, ADIA opened its flagship clinic in Winter Park, Florida, where it already offers treatments using umbilical cord stem cells (UCB-SC) to address conditions like Multiple Sclerosis, orthopedic injuries, and joint pain. The clinic exceeded financial expectations in its first month, covering all startup costs and proving that there is strong demand for its therapies. This success set the stage for further growth, including the opening of satellite locations across the country. ADIA’s medical division, Adia Med, is also making waves with its decision to offer Therapeutic Plasma Exchange (TPE) at all future full-service clinic locations. TPE, which removes harmful substances from a patient's blood, is being used to treat a variety of conditions, including Alzheimer’s disease. This is a major move in a rapidly growing field. According to ADIA’s CEO, Larry Powalisz, “Our current location is already delivering this therapy, and as we grow, every new full clinic equipped with top-tier apheresis machines will expand access to this innovative care.” This technology sets ADIA apart from other players in the field and positions the company to lead in advanced treatment options for patients with neurodegenerative diseases. Another area where ADIA is taking a leadership role is in the standardization of stem cell treatments. The company is working on setting new quality and safety standards for umbilical cord stem cell use in the United States. With many clinics offering subpar or non-viable stem cells, ADIA is aiming to make sure every patient gets stem cells that are live and effective. As CEO Larry Powalisz stated, “We’re crafting a movement for reliability and excellence.” The company plans to present its standards to the FDA and the Department of Health and Human Services, pushing for nationwide regulations that could transform the entire stem cell industry. On top of that, ADIA is preparing to expand internationally, as multiple overseas organizations have expressed interest in licensing the company’s treatments. The company is already in the process of reviewing the legal and regulatory steps required to bring its innovative therapies, like its flagship Adia Vita stem cell product, to other markets. ADIA’s international expansion could help it tap into a global market for regenerative medicine, offering the company even more room to grow. Lastly, ADIA’s asset-light expansion model is another key factor driving its growth. In March 2025, the company opened its first satellite clinic in Tinton Falls, New Jersey, in partnership with Keep Glowing Medical Spa and Dr. Michael Ellis. This shared space partnership allows ADIA to expand quickly without the overhead costs of building new clinics from the ground up. The Tinton Falls location will offer ADIA’s stem cell therapies, including Adia Vita and AdiaLink, to patients seeking advanced treatments for a variety of conditions. ADIA Nutrition’s combination of strong financial performance, strategic partnerships, and commitment to innovative treatments makes it an exciting stock to watch in the stem cell space. With its focus on quality, expanding treatment options, and international growth, ADIA is positioning itself to be a leader in regenerative medicine. Investors looking for a company with significant growth potential in this booming sector should keep an eye on ADIA as it continues to expand and evolve. Fate Therapeutics (NASDAQ: FATE) is a clinical-stage biopharmaceutical company that is making strides in developing stem cell therapies for both cancer and autoimmune diseases. The company's approach is built around induced pluripotent stem cells (iPSCs), which can be used to create cell therapies that are ready to be used right off the shelf. This eliminates some of the challenges of traditional stem cell treatments, which require personalized, patient-specific cells. By creating universal, off-the-shelf therapies, Fate aims to make stem cell treatments more accessible and cost-effective. One of the most promising candidates in Fate’s pipeline is FT819, a type of CAR T-cell therapy designed to treat autoimmune diseases, particularly systemic lupus erythematosus (SLE). FT819 is especially notable because it doesn’t require the usual chemotherapy conditioning that other CAR T-cell therapies do. Early trials of FT819 have shown strong potential. The first three patients treated with FT819 experienced no dose-limiting toxicities, and one patient even went into remission after the treatment. Bob Valamehr, Fate’s President of Research and Development, expressed his excitement over the results, saying, “We are pleased with the early clinical data, which continues to support the potential for disease transformation.” In addition, the FDA has allowed Fate to expand its trials to include additional autoimmune diseases, which could broaden the market for FT819 significantly. Fate’s pipeline doesn’t stop with FT819. The company is also advancing other therapies, like FT825 and FT522, which target different types of cancers. FT825 is designed to treat solid tumors, while FT522 focuses on blood cancers. Like FT819, these therapies aim to simplify the treatment process by avoiding the need for chemotherapy conditioning. FT522, for example, uses natural killer (NK) cells to target B-cell cancers, offering a promising new way to treat patients with difficult-to-treat cancers. On the financial side, Fate Therapeutics is well-funded, with $307 million in cash and investments at the end of 2024. This gives the company plenty of resources to continue advancing its clinical programs, and the company’s strong partnerships with firms like Ono Pharmaceutical further enhance its growth potential. With its innovative approach to off-the-shelf stem cell therapies, Fate Therapeutics is positioning itself as a leader in the field. Its therapies for autoimmune diseases and cancer are showing real promise, and with strong financial backing, the company is poised for continued progress in the years ahead. Mesoblast Limited (NASDAQ: MESO) is a global leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe, life-threatening inflammatory diseases. The company's therapies leverage its proprietary mesenchymal stromal cell (MSC) technology, which works by releasing anti-inflammatory factors to help modulate the immune system and reduce harmful inflammation. This technology is aimed at addressing conditions like steroid-refractory acute graft-versus-host disease (SR-aGvHD) and chronic heart failure, among others. Mesoblast's FDA-approved product, Ryoncil (remestemcel-L), is the first MSC-based therapy to gain approval for the treatment of pediatric patients with SR-aGvHD, a life-threatening condition that occurs after bone marrow transplants. In December 2024, the U.S. FDA approved Ryoncil for use in children as young as two months old, marking a significant milestone for the company. The therapy has demonstrated strong clinical results, with a 70% overall response rate in a Phase 3 trial and a survival rate of 49% at four years for children treated with Ryoncil. The company is also working on expanding Ryoncil’s applications to other inflammatory diseases, such as adult SR-aGvHD and biologic-resistant inflammatory bowel disease (IBD). Furthermore, Mesoblast is advancing its second key product, Rexlemestrocel-L (Revascor), which is being studied for chronic heart failure and chronic low back pain. These treatments offer promising alternatives to existing therapies by addressing the underlying inflammation that often complicates these diseases. In terms of growth and financial stability, Mesoblast has been proactive in securing strategic partnerships and expanding its market presence. The company has agreements in key regions such as Japan, Europe, and China. Additionally, it has an extensive intellectual property portfolio, with over 1,000 granted patents covering MSC compositions, manufacturing methods, and therapeutic indications. Financially, Mesoblast is in a strong position, with a cash balance of $38 million at the end of 2024. The company raised an additional $161 million in a private placement, which bolsters its ability to continue advancing its research and development initiatives. Mesoblast’s CEO, Dr. Silviu Itescu, expressed his enthusiasm about the future, noting, "Our FDA-approved product Ryoncil will be available in the coming weeks to children with SR-aGvHD in need of life-saving therapy." Overall, Mesoblast’s strong pipeline of therapies and its leadership in the allogeneic cell medicine space position it as a promising company in the stem cell and regenerative medicine sectors. With its recent FDA approval and expanding commercial partnerships, Mesoblast is set to make a significant impact in treating inflammatory diseases globally. CRISPR Therapeutics (NASDAQ: CRSP) is a pioneer in gene editing, making history as the first company to bring a CRISPR-based therapy to market. The company’s flagship product, CASGEVY, was approved in multiple countries in late 2023 to treat sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT)—two serious genetic blood disorders. Since then, patient demand has been strong, with over 50 authorized treatment centers (ATCs) worldwide and more than 50 patients having initiated cell collection by the end of 2024. Looking ahead, 2025 is shaping up to be a big year for CRISPR Therapeutics. The company is working on next-generation gene-editing programs and expanding into new disease areas like oncology, autoimmune disorders, and cardiovascular diseases. CEO Samarth Kulkarni called 2025 a "milestone-rich year" with major clinical updates expected across the company’s pipeline. While CASGEVY’s commercial rollout continues, CRISPR Therapeutics is making progress on several other fronts. CTX112 is a next-generation CAR T-cell therapy for blood cancers and autoimmune diseases. Early results showed strong efficacy in lymphoma patients, earning it a Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. In cardiovascular disease, CTX310 and CTX320 are experimental therapies targeting cholesterol and lipoprotein(a), a genetic risk factor for heart disease. Clinical updates are expected in the first half of 2025. CTX211 is a gene-edited stem cell therapy for Type 1 diabetes (T1D), designed to free patients from insulin injections without needing long-term immune suppression. CRISPR Therapeutics ended 2024 with $1.9 billion in cash and investments, giving it a strong financial cushion to fund research and commercialization efforts. The company has also partnered with Vertex Pharmaceuticals on CASGEVY, benefiting from Vertex’s commercial expertise as they roll out the therapy globally. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by ADIA to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

April 02, 2025 07:00 AM Eastern Daylight Time

UNOS adds two members to its board of directors

United Network for Organ Sharing

Today, the United Network for Organ Sharing (UNOS) announced that its Board of Directors has unanimously approved two new board members, bringing the board complement to nine. Melina Davis and Mark Johnson will begin their terms on April 1, 2025, serving until September 30, 2028. They were approved by a full board vote on March 24. “I’m pleased to welcome Melina and Mark to the UNOS Board of Directors,” said Sue Dunn, chair of the UNOS board of directors. “They each have an incredible background that exemplifies UNOS’ strategic priorities and work to help save and improve lives.” Davis and Johnson bring decades of executive leadership to the UNOS Board of Directors, both within and outside of healthcare. Davis is the CEO and executive vice president of the Medical Society of Viriginia and Johnson is the former CEO of Averhealth and BetterMed Urgent Care. “I’m honored to join the UNOS Board of Directors. UNOS is an organization that’s committed to enhancing the lives and health of individuals. Together, with my fellow board members, I will advocate for innovative solutions, enhance donor awareness, and strive to improve the overall donation and transplant system,” said Davis. “By collaborating, we can advance our goal to give hope and a second chance to many individuals and their families. I look forward to engaging with the community and harnessing our collective expertise to drive meaningful change.” “It’s an honor to be appointed to the UNOS Board of Directors, and for the opportunity to work with UNOS’ CEO Maureen McBride and the UNOS team as they pursue strategic initiatives to provide critical, high-value organ sharing and transplant services,” said Johnson. “As the complex organ transplantation system undergoes change, UNOS’ breadth and depth of know-how, and its extensive relationships with transplant hospitals and other stakeholders, point to a bright future for UNOS and for the many patients who rely on critical organ donations. I look forward to contributing strategic, financial and capital deployment support to UNOS as it advances its mission.” Davis and Johnson join UNOS’ current seven-member board, whose term began on March 30, 2024: Sue Dunn, former CEO of Donor Alliance Bapu Jena, M.D., Ph.D., professor of health care policy at Harvard Medical School, internist at Massachusetts General Hospital Maryl Johnson, M.D., professor at the University of Wisconsin School of Medicine Irene Kim, M.D., director of the Comprehensive Transplant Center at Cedars-Sinai Jake Kouns, founder of RVAsec James Pittman, assistant vice president of transplant and dialysis services for HCA Healthcare Marie Quintero-Johnson, retired vice president of corporate development for Coca-Cola and kidney recipient About UNOS The United Network for Organ Sharing (UNOS) is a nonprofit organization that serves the organ donation and transplant system and broader public health community through its work developing new technologies and initiatives, conducting data-driven research and analysis, providing expert consulting services, advocating for patients, and being a leader in bringing communities together to save lives. Contact Details United Network for Organ Sharing Anne Paschke anne.paschke@unos.org Company Website https://unos.org

March 31, 2025 02:01 PM Eastern Daylight Time

Market Alert: Palatin's Disruptive Obesity Drug Combination Shows Groundbreaking Weight Loss Results in Phase 2 Topline Data (NYSE: PTN)

Global Markets News

Palatin Technologies* has unveiled compelling topline results from its Phase 2 study showing that patients receiving its obesity drug bremelanotide in combination with tirzepatide achieved a 4.4% weight reduction compared to just 1.6% for placebo—a highly statistically significant difference (p<0.0001). The eight-week trial demonstrated that combining these two mechanisms creates a synergistic effect, with 40% of patients in the combination group achieving at least 5% weight loss compared to 27% with tirzepatide alone. The economic potential of anti-obesity drugs is enormous, with the market expected to reach US$100 billion by 2030. As obesity rates continue to climb globally, with the number of obese individuals worldwide projected to increase from 980 million to nearly 2 billion from 2022 to 2035, innovative treatment approaches like Palatin's are positioning themselves in this rapidly expanding market. Perhaps most intriguing for the obesity treatment landscape, Palatin's data revealed that its drug effectively halted the rapid weight regain typically seen after stopping GLP-1/GIP therapy. This addresses one of the most significant challenges facing current obesity treatments, where patients often regain substantial weight after discontinuation. The economic potential of anti-obesity drugs is enormous, with the market expected to reach US$100 billion by 2030. As obesity rates continue to climb globally, with the number of obese individuals worldwide projected to increase from 980 million to nearly 2 billion from 2022 to 2035, innovative treatment approaches like Palatin's are positioning themselves in this rapidly expanding market. Palatin is advancing development of next-generation long-acting injectable and oral versions of its obesity compounds, with investigational new drug applications planned for late 2025 and clinical data expected in early 2026. The company is one of just two developing therapies targeting this specific biological pathway for obesity. This announcement follows recent positive news from Palatin's ulcerative colitis program and FDA orphan drug designation for its oral obesity compound for rare genetic obesity disorders, demonstrating the company's momentum across multiple therapeutic areas with significant unmet needs. Subscribe For More Alerts: https://newsletter.page/wallstreetalerts Recent Palatin Technologies News Highlights: Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177 Completion of Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis *DISCLAIMER: This alert is published by Wall Street Wire. Wall Street Wire does not provide financial or investment advice, and our content does not represent an offer to buy or sell securities. Wall Street Wire is a promotional content brand and its operators are not registered brokers, dealers, or investment advisers. This alert contains and is a form of paid promotional content for to Palatin Technologies and was produced as part of their paid subscription to Wall Street Wire’s distribution and promotional content services. This alert has not been reviewed or approved by Palatin Technologies prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms Contact Details Wall Street Wire Market Aerts Desk media.globalmarkets@gmail.com

March 31, 2025 09:19 AM Eastern Daylight Time

Coolidge Reagan Foundation Files Congressional Ethics, FEC, and DOJ Criminal Complaints Against Rep. Jasmine Crockett

Coolidge Reagan Foundation

The Coolidge Reagan Foundation (CRF), a First Amendment watchdog, has filed a series of complaints against Representative Jasmine Crockett (D-TX), alleging serious ethical and legal violations, including voter intimidation, fraudulent campaign contributions, and misconduct in office. The complaints, simultaneously submitted to the Federal Election Commission (FEC), the Office of Congressional Ethics (OCE), and the Department of Justice (DOJ), expose Rep. Crockett’s alleged illegal activities and efforts to undermine fair elections and democratic processes. “Rep. Crockett’s reckless rhetoric and open encouragement of political violence are not only unacceptable but dangerously irresponsible, stated Shaun McCutcheon, Chairman of the Coolidge Reagan Foundation. “While I am an advocate for Free Speech, the fact is no Member of Congress should be inciting attacks on American voters. You can’t call on your supporters to attack people any more than you can yell fire in a crowded theater. Her actions must be condemned and investigated.” “This is a blatant abuse of power and a direct assault on free and fair elections,” Dan Backer, Counsel to CRF added. “From voter intimidation to potentially fraudulent campaign financing, Rep. Crockett’s conduct raises serious legal and ethical concerns. The American people deserve accountability, and Crockett must answer for her unethical, potentially criminal, and just plain dirty acts.” The complaint filed with the Department of Justice highlights Rep. Crockett’s alarming rhetoric and online activity, which appear to violate the Federal Voting Rights Act prohibiting voter intimidation. On March 9, 2025, Crockett circulated an animated video through social media depicting a cartoon version of herself and Rep. Alexandria Ocasio-Cortez brutally attacking a Republican voter. This video, broadcast to hundreds of thousands of her followers, not only condones but seemingly encourages political violence against Republicans. Her public statements, including referring to "full-on combat," further demonstrate a pattern of incitement that places American voters at risk. CRF is calling on the DOJ to investigate these actions under 52 U.S.C. § 10307(b) and other applicable federal statutes. CRF's complaint to the FEC details an apparent scheme in which Rep. Crockett’s campaign committee, ‘Jasmine for US’, accepted and falsely reported contributions processed through ActBlue. The filing reveals that an elderly retiree, Mr. Randy Best of Plano, Texas, was listed as making over 2,500 contributions totaling more than $21,000 – including more than 50 to Crockett (transactions that Mr. Best’s wife denies ever occurred). The sheer volume and pattern of these donations suggest an elaborate money-laundering scheme orchestrated through ActBlue to funnel illegal contributions to Democratic candidates, including Rep. Crockett. CRF demands an immediate FEC investigation into these violations of 52 U.S.C. § 30122, which prohibits accepting contributions in the name of, or with the funds of, another. In addition to potential criminal and campaign finance violations, CRF has also filed a complaint with the Office of Congressional Ethics, asserting that Rep. Crockett has engaged in behavior that fails to reflect creditably on the U.S. House of Representatives. Her public threats against Republican officials, Tesla CEO Elon Musk, and former President Donald Trump (paired with the incendiary video) constitute a clear violation of House Rule XXIII, which mandates ethical conduct by Members. Furthermore, her acceptance of potentially fraudulent contributions through ActBlue raises serious concerns about her fitness for office and adherence to congressional financial disclosure requirements. Shaun McCutcheon further emphasized the seriousness of the complaints stating “Congresswoman Crockett’s actions are a disgrace to the office she holds. Inciting violence against political opponents and engaging in fraudulent campaign finance practices are violations that cannot be ignored. CRF will not stand idly by while elected officials break the law and erode trust in our institutions.” Dan Backer added “We have seen a disturbing trend where ActBlue is used as a willing conduit for a potentially 8 or 9 figure sum of illegal campaign money laundering, and Rep. Crockett’s campaign is just one example. The FEC must investigate this apparent scheme to launder funds in the names of unsuspecting donors. Additionally, her rhetoric and public statements demand a full review by the DOJ for potential voter intimidation violations.” CRF calls for swift action to hold Rep. Crockett accountable and protect the integrity of our democratic process. The news of these complaints was first reported by Fred Lucas in the Daily Signal. ### Please visit: https://www.coolidgereagan.org/ For more information or to schedule an interview with a CRF spokesperson, contact Dan Rene at 202-329-8357 or dan@danrene.com Contact Details Coolidge Reagan Foundation Dan Rene +1 202-329-8357 dan@danrene.com Company Website https://www.coolidgereagan.org/

March 28, 2025 09:00 AM Eastern Daylight Time

Ekshef.com Celebrates Three Years of Revolutionizing Healthcare Accessibility in Egypt

Rev Up Marketers

Ekshef.com, Egypt's top online doctor appointment booking website, celebrates its third anniversary with pride and reaffirms its commitment to making healthcare accessible and convenient for patients nationwide. Since its launch in 2022, the platform has successfully bridged the gap between medical professionals and patients, providing free, convenient appointment booking services. Founded by Khaled Khamis, a developer of science and software engineering and a visionary entrepreneur, Ekshef.com has grown exponentially over the past three years. Having graduated from the Faculty of Science (Chemistry & Microbiology) in 2004, Khamis transitioned into software engineering by 2008. His technical and healthcare background has propelled the success of Ekshef, and it has turned out to be a game-changer in Egypt's healthcare industry. Today, Ekshef.com boasts a network of over 11,000 certified physicians in Egypt's major capital cities such as Cairo, Giza, and Alexandria. By making it easier to search for doctors and easily book appointments, Ekshef.com enabled thousands of patients to easily take control of their healthcare needs with ease. “At Ekshef.com, we believe in leveraging technology to remove barriers in healthcare accessibility,” said Ekshef.com Founder and CEO Khaled Khamis. "Completing our third anniversary is an achievement, and we are committed to expanding our platform and optimizing the patient experience." According to Crunchbase, Ekshef.com has obtained a total of $250,000 in funds from unidentified angel investors. Funds have been significant in enhancing platform features, streamlining user experience, and increasing presence across Egypt's healthcare ecosystem. Through its solid tech foundation, Ekshef.com is able to empower patients to seek and book visits with specialists across all medical specializations, ranging from cardiology and dermatology to pediatrics and more. The website is designed to accommodate the evolving needs of patients, offering them an easy and quick way of reaching high-quality medical professionals. Patients seeking specialist consultation can search through a comprehensive database of doctors in Cairo and other major cities. This brings healthcare to all, more than ever before. Ekshef.com's user-friendly interface, doctor listings verified by professionals, and real-time appointment booking facility have made it a leading name in digital healthcare services. The quick growth of the company is a testament to the growing need for effective, technology-based solutions in Egypt's healthcare industry. As Ekshef.com enters its fourth year of activities, the company is eagerly awaiting the next wave of expansion and technical growth. The team continues to work hard to add more features, bring in newer offerings, and cover more unserved areas to give every patient access to high-quality healthcare with minimal waiting times. Our goal is to continue innovating with the needs of the patients and physicians," Khamis said. “We are dedicated to making healthcare more accessible, reliable, and seamless for every Egyptian.” About Ekshef.com Ekshef.com is Egypt’s fastest-growing doctor booking platform, revolutionizing healthcare access by connecting patients with trusted medical professionals across the country. Founded in 2022 by Khaled Khamis, Ekshef.com has rapidly expanded its network to over 11,000 doctors in major cities like Cairo, Giza, and Alexandria, making it easier than ever to find and book appointments with qualified specialists. To learn more and book an appointment, visit Ekshef.com. Contact Details Ekshef for information technology Khaled Khamis contact@ekshef.com Company Website https://ekshef.com/

March 27, 2025 02:57 PM Eastern Daylight Time

Image

Direxion Expands Single Stock Leveraged & Inverse ETF Lineup for Exposure to Eli Lilly & Palo Alto Networks

Direxion

Direxion, a pioneer in Single Stock Leveraged and Inverse ETFs, expanded its suite of high-powered trading tools with the launch of four new funds tracking the performance of Eli Lilly and Company (LLY) and Palo Alto Networks, Inc. (PANW). These funds provide traders with amplified, or inverse, exposure to two of the most dynamic sectors – pharmaceuticals and cybersecurity – through the Direxion Daily LLY Bull 2X Shares (Ticker: ELIL) and Direxion Daily LLY Bear 1X Shares (Ticker: ELIS), or the Direxion Daily PANW Bull 2X Shares (Ticker: PALU) and Direxion Daily PANW Bear 1X Shares (Ticker: PALD). “These new ETFs give active traders an edge, whether they want to double down on momentum, or hedge against volatility, in two industry-leading stocks,” said Douglas Yones, CEO of Direxion. “Eli Lilly’s innovation in healthcare, and Palo Alto Networks’ in cybersecurity, make them prime candidates for our growing suite of tactical trading tools. We remain committed to launching new ETF solutions for short-term traders, with more to come in the near future." As ground-breaking products built for active traders, Direxion’s pairs of single stock leveraged and inverse ETFs are meant to be used for short-term trading purposes. Leveraged and inverse single stock ETFs should not be viewed as buy and hold investments, but rather trading tools for traders with a high-risk tolerance. In addition, unlike traditional ETFs, or even other levered and/or inverse ETFs, these ETFs track the price of a single stock rather than an index, eliminating the benefits of diversification. All Direxion leveraged and inverse ETFs are intended only for investors with an in-depth understanding of the risks associated with seeking leveraged investment results, and who plan to actively monitor and manage their positions. There is no guarantee these ETFs will meet their objective. Please visit the Direxion Leveraged and Inverse ETF Education Center, where you will find educational brochures, videos, and a self-paced online course to help you understand if leveraged and inverse ETFs – including single stock ETFs – are right for you. About Direxion: Direxion equips investors who are driven by conviction with ETF solutions built for purpose and fine-tuned for precision. These solutions are available for a broad spectrum of investors, whether executing short-term tactical trades, or investing in thematic strategies. Direxion’s reputation is founded on developing products that precisely express market perspectives and allow investors to manage their risk exposure. Founded in 1997, the company has approximately $47.0 billion in assets under management as of December 31, 2024. For more information, please visit www.direxion.com. There is no guarantee that the Funds will achieve their investment objectives. For more information on all Direxion Shares ETFs, go to www.direxion.com, or call us at 866.301.9214. An investor should carefully consider a Fund’s investment objective, risks, charges, and expenses before investing. A Fund’s prospectus and summary prospectus contain this and other information about the Direxion Shares. To obtain a prospectus and summary prospectus call 866.476.7523 or visit our website at direxion.com. A Fund’s prospectus and summary prospectus should be read carefully before investing. Investing in the funds involves a high degree of risk. Unlike traditional ETFs, or even other leveraged and/or inverse ETFs, these leveraged and/or inverse single-stock ETFs track the price of a single stock rather than an index, eliminating the benefits of diversification. Leveraged and inverse ETFs pursue daily leveraged investment objectives, which means they are riskier than alternatives which do not use leverage. They seek daily goals and should not be expected to track the underlying stock’s performance over periods longer than one day. They are not suitable for all investors and should be utilized only by investors who understand leverage risk and who actively manage their investments. The Funds will lose money if the underlying stock’s performance is flat, and it is possible that the Bull Fund will lose money even if the underlying stock’s performance increases, and the Bear Fund will lose money even if the underlying stock’s performance decreases, over a period longer than a single day. Investing in the Funds is not equivalent to investing directly in LLY or PANW. Direxion Shares Risks – An investment in a Fund involves risk, including the possible loss of principal. Each Fund is non-diversified and includes risks associated with a Fund concentrating its investments in a particular security, industry, sector, or geographic region which can result in increased volatility. A Fund's investments in derivatives such as futures contracts and swaps may pose risks in addition to, and greater than, those associated with directly investing in securities or other investments, including imperfect correlations with underlying investments or the Fund's other portfolio holdings, higher price volatility and lack of availability. As a result, the value of an investment in a Fund may change quickly and without warning. Leverage Risk – The Bull Fund obtains investment exposure in excess of its net assets by utilizing leverage and may lose more money in market conditions that are adverse to its investment objective than a fund that does not utilize leverage. A total loss may occur in a single day. Leverage will also have the effect of magnifying any differences in the Fund’s correlation with LLY or PANW and may increase the volatility of the Bull Fund. Daily Correlation Risk - A number of factors may affect the Bull Fund’s ability to achieve a high degree of correlation with LLY or PANW and therefore achieve its daily leveraged investment objective. The Bull Fund’s exposure to LLY or PANW is impacted by LLY or PANW’s movement. Because of this, it is unlikely that the Bull Fund will be perfectly exposed to LLY or PANW at the end of each day. The possibility of the Bull Fund being materially over- or under-exposed to LLY or PANW increases on days when LLY or PANW is volatile near the close of the trading day. Daily Inverse Correlation Risk - A number of factors may affect the Bear Fund’s ability to achieve a high degree of inverse correlation with LLY or PANW and therefore achieve its daily inverse investment objective. The Bear Fund’s exposure to LLY or PANW is impacted by LLY or PANW’s movement. Because of this, it is unlikely that the Bear Fund will be perfectly exposed to LLY or PANW at the end of each day. The possibility of the Bear Fund being materially over- or under-exposed to LLY or PANW increases on days when LLY or PANW is volatile near the close of the trading day. Eli Lilly and Company Investing Risk – Issuer-specific attributes may cause an investment held by the Fund to be more volatile than the market generally. Eli Lilly and Company faces risks associated with: costly and uncertain research and development of its products; maintaining intellectual property protections; intense competition from multinational pharmaceutical companies, biotechnology companies, and lower-cost generic and biosimilar manufacturers; increasing government price controls and other public and private restrictions on pricing, reimbursement, and access for its drugs; the development of safety or efficacy concerns; among other risks.. Pharmaceutical Industry Risk – The profitability of pharmaceutical companies is highly dependent on the development, procurement and marketing of drugs and the development, protection and exploitation of intellectual property rights and other proprietary information. These companies may be significantly affected by the expiration of patents or the loss of, or the inability to enforce, intellectual property rights. Healthcare Sector Risk — Companies in the healthcare sector may be affected by extensive, costly and uncertain government regulation, rising costs of medical products and services, changes in the demand for medical products and services, an increased emphasis on outpatient services, limited product lines, industry innovation and/or consolidation, changes in technologies and other market developments. Palo Alto Networks, Inc. Investing Risk – Issuer-specific attributes may cause an investment held by the Fund to be more volatile than the market generally. Palo Alto Networks, Inc. faces risks associated with: development of new products and services may be difficult; may be unable to attract new customers; reliance on channel partners; credit and liquidity risk of customers; sales to government entities may be subject to greater scrutiny; intense competition; among other risks. Information Technology Sector Risk — The value of stocks of information technology companies and companies that rely heavily on technology is particularly vulnerable to rapid changes in technology product cycles, rapid product obsolescence, government regulation, and competition, both domestically and internationally, including competition from competitors with lower production cost. Additional risks of each Fund include Effects of Compounding and Market Volatility Risk, Derivatives Risk, Counterparty Risk, Rebalancing Risk, Intra-Day Investment Risk, Industry Concentration Risk, Market Risk, Indirect Investment Risk, and Cash Transaction Risk. Additionally, for the Direxion Daily LLY Bear 1X Shares and Direxion Daily PANW Bear 1X Shares, Shorting or Inverse Risk. Please see the summary and full prospectuses for a more complete description of these and other risks of a Fund. Distributor: ALPS Distributors, Inc. Contact Details Ditto Public Relations Danielle Black, AD direxion@dittopr.co Company Website https://www.direxion.com/

March 26, 2025 09:00 AM Eastern Daylight Time

XVesuvius Named Men's Health "Best Acne Product"

XVolcano

XVolcano's flagship product, XVesuvius, has been named the Men's Health 2025 Grooming Award Winner for "Best Acne Product," recognizing its innovative approach to treating acne with a proprietary combination of clinical-strength active ingredients. “Out of all the acne products our testers tried, they said this one was most effective at attacking active breakouts. One application in the morning and one at night was all it took to erase zits in as little as a day,” said Men’s Health. This prestigious honor acknowledges XVesuvius's effectiveness, particularly for athletes and active individuals dealing with stubborn acne. "We're thrilled to receive this recognition from Men's Health," said Steve Dworman, Founder of XVolcano. "XVesuvius was developed to address multiple aspects of skin health with clinical-strength ingredients. Our formula was created to not only clear acne but to improve overall skin health through clinically-validated ingredients that target multiple pathways simultaneously." XVesuvius represents a breakthrough in skincare through its innovative combination of clinically-validated ingredients at full clinical strength. Based on research shared by board-certified dermatologists, XVesuvius delivers comprehensive skin transformation through seven key mechanisms: - Advanced Antimicrobial Activity Without Antibiotics - Superior Hydration Technology - Powerful Anti-Inflammatory Properties - Sebum Regulation - Advanced Anti-Scarring Technology - Hyperpigmentation Reduction - Comprehensive Anti-Aging Effects "What makes XVesuvius truly revolutionary is its comprehensive approach to skin health," noted Dr. Serena Mraz, a board-certified, Stanford-trained dermatologist who has evaluated the product. "The formula contains a rich combination of potent ingredients that address multiple components of acne, acne sequelae, and aging changes with skin health-boosting effects. Most skincare regimens require 4-5 different products to achieve what XVesuvius accomplishes in one formula." About XVolcano XVolcano is dedicated to developing innovative skincare solutions that address specific challenges faced by athletes and active individuals. The company's flagship product, XVesuvius, combines cutting-edge skincare science with practical formulations designed for real-world use. For more information, visit www.xvolcano.com. Contact Details Farrington PR Kim Farrington kim@farringtonpr.com Company Website https://xvolcano.com/

March 20, 2025 08:30 AM Eastern Daylight Time

Image

Market Alert: Inspira Technology Gains Industry Exposure as FDA-Cleared Technology Showcased at Major Conference

Global Markets News

Market News Alerts Reports: Inspira Technologies (NASDAQ: IINN)* is gaining attention today as their FDA-cleared INSPIRA™ ART100 life-support system is being showcased at the prestigious AmSECT International Conference in San Diego, potentially exposing their technology to hundreds of perfusion professionals. This high-profile exhibition comes at a strategic moment for Inspira, with recent developments showing momentum: The FDA-cleared INSPIRA ART100 system is being prepared for deployment in leading U.S. hospitals Recent clinical studies demonstrated 96% accuracy for their HYLA blood sensor technology The company is advancing development of their flagship INSPIRA ART500 system With the company visionairy approach targeting approximately 20 million ICU patients with acute respiratory failure annually worldwide, Inspira aims to address significant markets: the $5.7B blood gas analyzer market and the $19B mechanical ventilation sector. The company's approach allows patients to remain awake during treatment without ventilators—addressing a need where current solutions face significant challenges. This conference appearance raises Inspira's profile within the perfusion community, potentially supporting their commercialization strategy as they work to introduce their technology to medical institutions. * Disclaimer: Nothing in this report constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This report is published Market News Alerts Research, a promotional content brand which is part of the Wall Street Wire™ network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This distribution contains paid promotional content related to Inspira Technologies and was produced as part of their paid subscription to Wall Street Wire. This report has not been reviewed or approved by Inspira prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms. Contact Details Markets News Alerts Editorial Desk globalmarkets.media@gmail.com

March 19, 2025 11:28 AM Eastern Daylight Time

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug

Global Markets News

NeuroSense's Groundbreaking ALS Combination Therapy PrimeC Advances Towards commercialization in Canada potential for revenue in canada alone of $100-150 million dollars. PrimeC Has Previously Demonstrated Unprecedentedly Strong Clinical Efficacy; Market News Alerts Reports -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN)* has announced significant progress toward the early commercialization of PrimeC in Canada. According to a Form 6-K filed with the SEC this morning, Health Canada has invited the company to a pre-New Drug Submission (pre-NDS) meeting to discuss a potential Notice of Compliance/conditional (NOC/c) regulatory pathway for PrimeC as a treatment for Amyotrophic Lateral Sclerosis (ALS). NeuroSense is targeting potential approval in Canada by H1 2026. The company estimates peak annual revenue potential of $100-150M USD in the Canadian market. This meeting marks a critical step in NeuroSense's regulatory strategy for PrimeC PrimeC is NeuroSense's lead drug candidate for ALS, a novel extended-release oral formulation combining ciprofloxacin and celecoxib. The drug has demonstrated promising results in clinical trials, including the Phase 2b PARADIGM study, which showed a 36% reduction in disease progression and 43% improvement in survival rates compared to placebo. In December 2024, NeuroSense reported positive FDA feedback on its Phase 3 trial design for PrimeC, with plans to initiate the pivotal study in mid-2025. The company has also announced entering a binding term sheet with a global pharmaceutical company to advance PrimeC's development, which includes substantial upfront payments and funding for the Phase 3 program. This Canadian regulatory development represents a potential pathway to earlier commercialization while the larger Phase 3 program proceeds for global markets. The neurodegenerative disease treatment market has witnessed transformative licensing deals that highlight the immense value of innovative therapies. GlaxoSmithKline's 2021 collaboration with Alector set a remarkable precedent with a $700 million upfront payment and potential milestone payments of $1.5 billion, while the Biogen and Denali Therapeutics partnership in 2020 involved $560 million upfront and potential milestones approaching $1.125 billion. These deals underscore the pharmaceutical industry's willingness to invest heavily in breakthrough neurological innovations, potentially like NeuroSense's PrimeC. Some Wall Street Analysts reportedly maintain a Buy Rating for NeuroSense with AGP giving the company a $7.50 price target representing a significant premium over current Prices; * Disclaimer: Nothing in this report constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This alert is published by Market News Alerts, a promotional content brand which is part of the Wall Street Wire™ network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This distribution is paid promotional content related to NeuroSense Therapeutics and was produced as part of their paid subscription to Wall Street Wire. This report has not been reviewed or approved by NeuroSense Therapeutics prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms. We are not responsible for the price targets mentioned in this article nor do we it endorse them, they are quoted based on publicly available news reports and additional or price targets may exist that may not have been quoted. Readers are advised to refer to the full reports mentioned on various systems and the disclaimers/disclosures they may be subject to. Contact Details Market News Alerts Editorial Desk globalmarkets.media@gmail.com

March 19, 2025 11:01 AM Eastern Daylight Time